These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 22269418

  • 1. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
    Kapoor R, Khosla D, Kumar P, Kumar N, Bera A.
    J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
    [No Abstract] [Full Text] [Related]

  • 2. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract] [Full Text] [Related]

  • 3. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
    Caram MV, Schuetze SM.
    J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
    [Abstract] [Full Text] [Related]

  • 4. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib for imatinib-resistant GIST.
    Joensuu H.
    Lancet; 2006 Oct 14; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract] [Full Text] [Related]

  • 6. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
    Nishida T, Yoshidome K, Tori M.
    Nihon Rinsho; 2012 Nov 14; 70 Suppl 8():452-6. PubMed ID: 23513883
    [No Abstract] [Full Text] [Related]

  • 7. Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    De Giorgi U.
    Future Oncol; 2013 Nov 14; 9(11):1675-7. PubMed ID: 23862700
    [No Abstract] [Full Text] [Related]

  • 8. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG.
    Curr Oncol Rep; 2007 May 14; 9(3):165-9. PubMed ID: 17430686
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of regorafenib in colorectal cancer and GIST.
    Waddell T, Cunningham D.
    Lancet; 2013 Jan 26; 381(9863):273-5. PubMed ID: 23177516
    [No Abstract] [Full Text] [Related]

  • 10. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov 26; 29(11):875-7. PubMed ID: 18396652
    [No Abstract] [Full Text] [Related]

  • 11. Gastrointestinal stromal tumors: current management.
    Pisters PW, Patel SR.
    J Surg Oncol; 2010 Oct 01; 102(5):530-8. PubMed ID: 20063363
    [Abstract] [Full Text] [Related]

  • 12. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J.
    BMC Cancer; 2012 Mar 22; 12():107. PubMed ID: 22439647
    [Abstract] [Full Text] [Related]

  • 13. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P.
    Ann Oncol; 2012 Jul 22; 23(7):1680-7. PubMed ID: 22357255
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators.
    Lancet; 2013 Jan 26; 381(9863):295-302. PubMed ID: 23177515
    [Abstract] [Full Text] [Related]

  • 15. Current management of GISTs.
    Blanke C.
    Clin Adv Hematol Oncol; 2010 May 26; 8(5):334. PubMed ID: 20551892
    [No Abstract] [Full Text] [Related]

  • 16. [A case of imatinib-resistant GIST treated by sunitinib].
    Sakamoto Y, Akimoto H, Kojo M, Kawano H, Chinen Y, Morita K, Sugiyama M, Saeki H, Minami K, Soejima Y, Sakaguchi Y, Toh Y, Okamura T.
    Gan To Kagaku Ryoho; 2011 May 26; 38(5):827-30. PubMed ID: 21566447
    [Abstract] [Full Text] [Related]

  • 17. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
    Wang CM, Fu H, Zhao GF, Wang J, Shi YQ.
    Pathol Oncol Res; 2012 Oct 26; 18(4):1095-7. PubMed ID: 21927980
    [No Abstract] [Full Text] [Related]

  • 18. Gastrointestinal stromal tumour.
    Rubin BP, Heinrich MC, Corless CL.
    Lancet; 2007 May 19; 369(9574):1731-41. PubMed ID: 17512858
    [Abstract] [Full Text] [Related]

  • 19. Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy.
    Dizdar O, Yalcin S.
    Hepatogastroenterology; 2011 May 19; 58(112):2012-4. PubMed ID: 22024073
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
    Svetlichnaya J, Huyck TK, Wayne JD, Agulnik M.
    Chemotherapy; 2012 May 19; 58(1):30-3. PubMed ID: 22415035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.